Medically Supervised Relapse Prevention: What Happens After Detox or Rehab?
No opioid-free waiting window before starting treatment at DeBinge When travelling to DeBinge in The Bahamas for OLANI treatment, there is no requirement to complete a separate opioid-free waiting window before arrival. DeBinge uses a medically supervised 4-to-5-day buprenorphine transition. Buprenorphine is introduced to bridge the patient away from full-agonist opioids, stabilised and tapered over the first several days, and the O’Neil Long-Acting Naltrexone Implant is typically inserted around day 4 or 5 while buprenorphine is still being tapered. The planned overlap continues as buprenorphine clears and the implant gradually releases naltrexone. This pathway is clinician-supervised because mistimed naltrexone exposure can precipitate withdrawal.
Based on DeBinge’s clinical experience in The Bahamas since 2018, the implant typically provides its strongest craving and relapse-prevention support on average 9 months, while clinically meaningful opioid-receptor blockade may persist for longer, in some patients up to about 15 months. This longer blockade may continue to reduce opioid effects and overdose risk.
Ongoing recovery: The implant is not a cure. The DeBinge programme includes a full year of professional counselling after implantation to address the behavioural and psychological side of addiction.
Detoxification or residential rehab can be an important beginning, but neither one automatically provides the long-term treatment needed after acute stabilization. Medically supervised relapse prevention is a continuing-care process that can combine reassessment, medication, counselling, mental-health care, overdose-prevention planning, family support, environmental change and rapid clinical response if substance use returns.
It is not a single medication, procedure or promise that relapse will never occur. The goal is to reduce risk, improve treatment retention, identify problems early and make recovery more sustainable after the intensive phase of care has ended.
A person can complete detox successfully and still remain at substantial risk of returning to alcohol or opioids. Continuing treatment should therefore begin before discharge whenever possible, rather than waiting for cravings, stress or substance use to become severe again.
What Is Medically Supervised Relapse Prevention?
Medically supervised relapse prevention is structured continuing treatment after detoxification, inpatient care, residential rehab or another period of stabilization. It focuses on the clinical factors that continue after withdrawal has settled.
Depending on the person, the plan may include medication for opioid use disorder or alcohol use disorder, psychiatric treatment, counselling, monitoring of adherence and side effects, overdose-prevention planning, family involvement and regular reassessment.
This is different from a personal relapse-prevention plan. A personal plan may identify triggers, warning signs, coping strategies and supportive people. Those are valuable and are covered in the DeBinge resource on personal relapse-prevention planning.
This page focuses on a different question: What clinical treatment should continue after detox or rehab, and how should that treatment be supervised over time?
Relapse Prevention Is More Than One Medication
Medication can be extremely important, but a comprehensive continuing-treatment plan usually considers several interconnected areas.
Medical Reassessment
Review current substance use, withdrawal status, medications, physical health, mental health and treatment goals.
Medication
Consider evidence-based pharmacotherapy where appropriate and review whether it is working, tolerated and practical.
Counselling
Continue behavioural treatment rather than assuming medication alone resolves the psychological drivers of substance use.
Mental Health
Identify depression, anxiety, trauma, sleep problems or other conditions that may affect relapse risk and treatment retention.
Environment
Address access to substances, unstable housing, high-risk relationships, isolation and routines that repeatedly expose the patient to triggers.
Adherence
Ask whether the treatment plan is realistic enough to follow consistently, including appointments and medication.
Safety
Include naloxone where opioid exposure is possible and discuss reduced opioid tolerance after periods of abstinence.
Early Response
Decide what happens if cravings increase, appointments are missed or substance use returns.
Medical Reassessment After Detox or Rehab
Discharge from detox or rehab should not be treated as the end of clinical decision-making. A patient’s needs can change quickly during early recovery.
A continuing-care assessment may review current substance use, how recently alcohol or opioids were used, medications received during detox, withdrawal complications, previous relapse patterns, overdose history, medical conditions, liver health where relevant, pregnancy status, psychiatric symptoms and what treatments have or have not worked before.
The clinician should also ask what the patient actually wants. Some people want complete abstinence. Others may initially be focused on preventing overdose, reducing alcohol consumption, stabilizing work or family life or staying engaged in treatment.
Continuing care works best when the plan is reassessed rather than treated as a fixed programme that must remain unchanged regardless of the patient’s progress or circumstances.
Medication Options for Opioid Relapse Prevention
For opioid use disorder, medication is often one of the most important components of ongoing treatment. Evidence-based options include buprenorphine, methadone and extended-release naltrexone.
These medications work differently and should not be presented as if one option is automatically appropriate for every patient.
Buprenorphine
Buprenorphine is a partial opioid agonist. It can reduce withdrawal symptoms and cravings while helping stabilize opioid receptor activity.
It can be continued as maintenance treatment rather than used only briefly for detoxification. For many patients, remaining on effective buprenorphine is medically appropriate.
A person should not be encouraged to stop stable buprenorphine treatment simply to become eligible for antagonist treatment such as naltrexone.
Methadone
Methadone is a full opioid agonist used in structured treatment of opioid use disorder. It can reduce illicit opioid use, improve retention and help stabilize patients whose opioid dependence is severe or persistent.
For someone doing well on methadone, there may be no clinical reason to discontinue it merely because another medication is available.
Any transition away from methadone should be medically planned because physical dependence can persist and naltrexone initiation too soon can precipitate severe withdrawal.
Extended-Release Naltrexone
Extended-release injectable naltrexone is an opioid antagonist that blocks opioid receptors rather than activating them. It is generally administered at approximately monthly intervals.
Unlike buprenorphine and methadone, naltrexone requires the patient to be sufficiently opioid-free before initiation. Starting it while significant opioid physical dependence remains can cause precipitated withdrawal.
The induction period can therefore be a major clinical consideration, particularly after fentanyl exposure or when transitioning from methadone or buprenorphine.
Choosing Among Options
Medication choice can depend on patient preference, previous response to treatment, current physical dependence, ability to complete naltrexone induction, access to treatment, adherence concerns and other medical factors.
People who prefer antagonist treatment may consider naltrexone once clinically ready. Others may benefit more from ongoing agonist treatment.
For a more focused discussion of antagonist treatment after opioid dependence, see the DeBinge guide to long-acting naltrexone and opioid use disorder.
Transitions between opioid-use-disorder medications should be clinically supervised. The appropriate opioid-free interval varies and can be especially difficult to predict after fentanyl exposure.
Medication Options After Alcohol Detox
Alcohol detoxification treats the acute withdrawal period. It does not by itself treat the long-term biological and behavioural risk of returning to harmful drinking.
Medication options for alcohol use disorder can include naltrexone, acamprosate and disulfiram, depending on the patient.
| Medication | General Role | Important Considerations |
|---|---|---|
| Naltrexone | Can reduce the reinforcing effects of alcohol and may help reduce heavy drinking or support abstinence. | It does not treat acute alcohol withdrawal. Opioid use must also be considered because naltrexone blocks opioid receptors. |
| Acamprosate | Used to support maintenance of abstinence after alcohol withdrawal has resolved. | Dosing frequency and renal function can affect suitability and adherence. |
| Disulfiram | Creates an aversive reaction if alcohol is consumed and may be useful for selected, motivated patients. | Requires careful counselling, medical consideration and often works best when adherence is structured or supervised. |
Medication selection should take account of drinking goals, liver and kidney health, current opioid use, previous treatment response, adherence and patient preference.
No medication should be presented as a substitute for medically appropriate alcohol-withdrawal management. Alcohol withdrawal can be dangerous, and naltrexone does not prevent alcohol-withdrawal seizures or delirium tremens.
For more detail about sustained-release naltrexone in the context of alcohol use disorder, see Naltrexone Implant for Alcohol Use Disorder: What Does the Evidence Actually Show?
Where Do Long-Acting Naltrexone Implants Fit?
Sustained-release naltrexone implants are designed to release naltrexone over a prolonged period after placement beneath the skin. Their main theoretical advantage is adherence: the patient does not have to remember a daily tablet or return every month for an injection while clinically meaningful medication exposure continues.
However, “naltrexone implant” does not describe one universal product. Different formulations can vary in dose, implant material, release characteristics, intended duration and clinical evidence.
Naltrexone implant formulations are not FDA-approved for clinical use in the United States. FDA-approved U.S. naltrexone options include oral formulations and extended-release injectable naltrexone.
Published studies of sustained-release implants have reported benefits in some populations, but evidence should be interpreted according to the exact formulation studied. Implant treatment should not be presented as universally superior to methadone, buprenorphine, oral naltrexone or extended-release injectable naltrexone.
A 2025 Cochrane review of sustained-release naltrexone included a mixture of implant and injectable formulations. Results supported benefit in some outcomes, but evidence certainty varied, reinforcing the importance of product-specific interpretation rather than broad claims about all implants.
For a fuller explanation, see:
- Long-Acting Naltrexone Implant: Uses, Duration, Safety and Evidence
- Naltrexone Implant vs Oral Naltrexone vs Vivitrol
- U.S. Availability vs Naltrexone Implant Treatment in The Bahamas
A long-acting medication can reduce one adherence problem, but it does not replace counselling, psychiatric treatment, family support, overdose-prevention planning or continuing clinical review.
Naloxone Still Matters When Opioid Exposure Is Possible
Periods of abstinence can reduce opioid tolerance. If someone later returns to opioid use, an amount that was previously tolerated may become dangerous.
Naloxone should therefore remain part of safety planning whenever opioid exposure is possible, including after detox, residential treatment and antagonist treatment.
Naltrexone can reduce or block opioid effects while adequate antagonist concentrations are present, but attempting to overpower the blockade with very large opioid doses is dangerous. Protection should never be described as absolute.
Patients and families should know where naloxone is kept, how to recognize an overdose and when to call emergency services.
Medication Works Within a Larger Recovery System
Relapse risk is rarely driven by pharmacology alone. Stress, grief, trauma, depression, anxiety, insomnia, relationship conflict, loneliness and unstable living conditions can all influence substance use.
Counselling can help patients understand triggers, improve coping strategies, rebuild routines, address interpersonal problems and respond differently to cravings or high-risk situations.
Mental-health assessment is equally important. Untreated psychiatric symptoms can make it difficult to follow medication plans, attend appointments or maintain recovery structure.
Counselling
Regular sessions can support behavioural change, accountability and early identification of relapse warning signs.
Psychiatric Care
Depression, anxiety, trauma-related symptoms or other psychiatric conditions may require assessment and treatment in their own right.
Sleep and Routine
Irregular sleep, isolation and unstructured time can undermine recovery even when medication adherence is good.
What Happens When the Patient Returns to the Same Environment?
A person may leave detox physiologically stable but return to the same home, relationships, dealers, drinking culture, financial stress or isolation that existed before treatment.
Continuing care should therefore examine whether the recovery environment makes the treatment plan realistic.
Useful clinical questions include:
- Is alcohol or opioid access immediate?
- Does the patient live with people who regularly use substances?
- Is there a stable place to sleep?
- Is work creating extreme fatigue or stress?
- Does the person have meaningful daily structure?
- Are appointments realistically accessible?
- Who notices early warning signs?
Clinical relapse prevention may therefore involve practical changes as well as medication.
A Treatment Cannot Help if It Is Impossible to Follow
Adherence problems should not automatically be interpreted as a lack of motivation. A patient may miss medication because of side effects, cost, transport, work schedules, stigma, unstable housing or simply because the treatment plan is too complicated.
Medical supervision should identify these barriers rather than waiting until the person disengages completely.
Long-acting formulations may reduce some medication-adherence demands, but they do not solve every form of treatment disengagement. A patient can still stop counselling, miss follow-up, become isolated or avoid seeking help when risk increases.
“Can this person realistically follow this treatment plan for the next six months?” If the answer is no, the plan may need to change.
How Can Family Support Fit Into Clinical Relapse Prevention?
Family involvement can be helpful when the patient wants it and confidentiality boundaries are respected.
A family member may help recognize warning signs, support appointment attendance, keep naloxone available, reduce access to substances or provide practical support during difficult periods.
Family members also need realistic expectations. Medication does not create a guarantee that substance use will never return, and constant surveillance can damage trust.
A better approach is to agree in advance what signs should trigger a conversation or clinical review and what information the patient has consented to share.
A Return to Use Should Trigger Reassessment, Not Automatic Discharge
One of the most important parts of medically supervised relapse prevention is deciding what to do if substance use returns.
An episode of drinking or opioid use does not automatically mean that every part of treatment has failed. It may indicate that medication needs adjustment, adherence has changed, the environment has become more risky, psychiatric symptoms have worsened or the patient needs a more intensive level of support.
Early response can include:
- rapid clinical contact;
- reassessment of overdose and withdrawal risk;
- review of medication adherence and effectiveness;
- additional counselling;
- mental-health reassessment;
- increased appointment frequency;
- consideration of another level of care;
- renewed naloxone planning if opioids are involved.
Waiting until substance use becomes severe again can turn a manageable treatment adjustment into a crisis.
Long-Acting Naltrexone Within a Broader Continuing-Care Plan
DeBinge provides implant-based treatment in Nassau, The Bahamas. DeBinge does not operate implant clinics in U.S. cities.
For a patient considering antagonist treatment, the process should begin with medical assessment rather than an assumption that an implant is automatically the right choice.
Clinical planning may need to consider current opioid dependence, fentanyl exposure, methadone or buprenorphine use, alcohol use, other medications, medical conditions and whether the patient can safely transition to naltrexone.
Long-acting naltrexone can form one component of relapse-prevention treatment for a suitable patient, but counselling, follow-up, mental-health care, recovery structure and overdose-safety planning remain important.
Continuing treatment should be planned before the crisis returns.
Patients considering long-acting naltrexone can use a consultation to discuss medication options, preparation requirements, counselling, follow-up and whether international treatment is appropriate before making a travel decision.
Learn About Long-Acting Naltrexone Understand Treatment in The BahamasWhich Parts of Your Continuing Treatment Plan Need Discussion?
This educational tool does not diagnose a substance use disorder, select a medication or determine the appropriate level of care. It identifies areas that may be useful to discuss with a qualified clinician.
Your selections are processed only inside your browser and are not submitted to DeBinge.
Has a clinician reviewed your current substance use, medications and medical condition since detox or rehab?
Have you discussed evidence-based medication options appropriate to opioid or alcohol use disorder?
Do you have ongoing counselling or behavioural support after the intensive treatment period?
Have depression, anxiety, trauma, sleep or other mental-health concerns been assessed as part of continuing care?
Has your treatment plan considered your home environment, access to substances and daily routine?
Is your medication and appointment plan realistic enough to follow consistently?
If opioid exposure is possible, has naloxone and reduced opioid tolerance been discussed?
Have you decided whether a trusted family member or support person should be involved in continuing care?
Do you know who will review your treatment over the next several months?
Is there a clear plan for what happens if cravings intensify or substance use returns?
Topics to Review With Your Treatment Team
Your answers identify areas that may benefit from further discussion. They do not provide a diagnosis or medication recommendation.
A plan that worked immediately after detox may need to change as recovery, medical needs, work, relationships or relapse risk change.
Medically Supervised Relapse Prevention FAQ
Is detox enough to prevent relapse?
No. Detoxification manages the acute withdrawal period. It does not by itself address the longer-term biological, psychological, social and environmental factors associated with opioid or alcohol use disorder.
What medications can help prevent opioid relapse?
Evidence-based medication options for opioid use disorder include buprenorphine, methadone and extended-release naltrexone. The appropriate option depends on the individual and should be selected with a qualified clinician.
What medications are used after alcohol detox?
Naltrexone, acamprosate and disulfiram are among medications that may be considered for alcohol use disorder depending on the patient’s goals, medical history and clinical circumstances.
Does naltrexone treat alcohol withdrawal?
No. Naltrexone is not a treatment for acute alcohol withdrawal and does not prevent alcohol-withdrawal seizures or delirium tremens. Withdrawal may require specific medical management.
Are naltrexone implants FDA-approved in the United States?
No. Naltrexone implant formulations are not FDA-approved for clinical use in the United States. FDA-approved U.S. naltrexone options include oral formulations and extended-release injectable naltrexone.
Is a naltrexone implant better than methadone or buprenorphine?
Not universally. These treatments work differently and suitability depends on patient preference, physical dependence, previous response, access, adherence and other clinical factors. Patients doing well on methadone or buprenorphine should not be encouraged to stop solely to obtain an implant.
Why is naloxone still important after rehab?
Opioid tolerance can decline during abstinence. If opioid use later returns, previously tolerated amounts can become dangerous. Naloxone remains an important overdose-prevention measure whenever opioid exposure is possible.
What should happen if substance use returns?
Return to use should prompt rapid reassessment of safety, medication, mental health, adherence, environment and level of care. It should not automatically be treated as proof that all treatment has failed.
Evidence-Based Guidance
FDA: Medications for Opioid Use Disorder
FDA information on approved opioid-use-disorder medications, including buprenorphine, methadone and extended-release injectable naltrexone.
SAMHSA: Naltrexone
SAMHSA information on naltrexone, opioid-free preparation and use as part of comprehensive substance-use treatment.
ASAM National Practice Guideline
Clinical guidance addressing medication treatment for opioid use disorder and continuing care.
2025 Cochrane Review
Systematic review evaluating sustained-release naltrexone formulations for opioid dependence.
Medication choice, regulatory status and treatment guidance can change over time. Patients should confirm current information with their treating clinician and relevant healthcare regulator.
Prepared for Medical Review by Dr Fergus Law, BSc, MBChB, FRCPsych
Consultant Psychiatrist specialising in substance misuse and addiction psychiatry.
This article has been prepared as an evidence-based educational resource and is awaiting formal clinical approval. Until that review has been completed, it should not be described as medically reviewed.
View Dr Fergus Law’s professional profile
Review status: Pending clinical approvalThis Page Does Not Replace Individual Medical Care
This article is educational and does not determine which medication, level of care or relapse-prevention strategy is appropriate for a particular person.
Do not abruptly stop methadone, buprenorphine, alcohol, opioids or other prescribed medications based on this page. Alcohol withdrawal and opioid-medication transitions can require medical supervision.
If a person is unconscious, breathing abnormally, suspected of opioid overdose, experiencing severe withdrawal, having a seizure or facing another medical emergency, seek immediate local emergency assistance.